Iterum Therapeutics PLC (ITRM)
Stock Price:
$1.19 USD
0.00 (0.00%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
21.23M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-98.65M |
| Shares Out |
17.84M |
| EPS (ttm) |
-6.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$1.19 |
| Previous Close |
$1.19 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
1.18 |
| Day's Range |
1.12 - 1.20 |
| Day's Volume |
2,074,884 |
| 52-Week Range |
1.12 - 7.65 |
More Stats
| Market Cap |
21.23M |
| Enterprise Value |
33.67M |
| Earnings Date (est) |
Aug 12, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
17.84M |
| Float |
9.72M |
| EPS (basic) |
-6.74 |
| EPS (diluted) |
-6.73 |
| FCF / Share |
-6.14 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
366,880 |
| Short Ratio |
0.18 |
| Short % of Float |
4.10% |
| Beta |
1.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
-94.45M |
| Net Income |
-98.65M |
| Free Cash Flow |
-91.24M |
| Net Cash |
-12.44M |
| Net Cash / Share |
-0.70 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-89.82% |
| ROE |
-1,995.15% |
| ROIC |
-3,758.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
1 |
| Overweight |
0 |
| Hold |
3 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$4.75*
(299.16% upside)
Low
1.00
Current: 1.19
High
9.00
Target: 4.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 0.04 | 0.87 | 0.51 | - |
| Revenue Growth | -95.74% | 71.06% | - | - |
| Gross Profit | 0.04 | 0.87 | 0.51 | - |
| Operating Income | -102 | -76.56 | -29.46 | -13.36 |
| Net Income | -103 | -77.06 | -29.41 | -13.46 |
| Shares Outstanding | 14.52 | 8.73 | 0.17 | 0.02 |
| Earnings Per Share | -7.10 | -8.82 | -170.84 | -568.87 |
| Operating Cash Flow | -78.89 | -75.89 | -30.60 | -11.30 |
| Capital Expenditures | -0.02 | -0.09 | -0.81 | - |
| Free Cash Flow | -78.91 | -75.98 | -31.42 | -11.30 |
| Cash & Equivalents | 4.83 | 84.58 | 39.22 | 24.81 |
| Total Debt | 13.43 | 14.10 | - | - |
| Net Cash / Debt | -8.59 | 70.48 | 39.22 | 24.81 |
| Assets | 25.75 | 97.87 | 46.76 | 26.92 |
| Liabilities | 51.99 | 26.25 | 7.21 | 4.22 |
| Book Value | -26.24 | 71.62 | 39.49 | 22.67 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Iterum Therapeutics PLC |
| Country |
Ireland |
| Employees |
44 |
| CEO |
Corey N. Fishman |
Stock Information
| Ticker Symbol |
ITRM |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ITRM |
| IPO Date |
May 25, 2018 |
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.